Table 4 Cardiovascular events (CVEs).
Nilotinib 300 mg twice daily | Nilotinib 400 mg twice daily | Imatinib 400 mg once daily | |
|---|---|---|---|
CVEs, na | 279 | 277 | 280 |
Cumulative CVEs | |||
All CVEs | 46 (16.5) | 65 (23.5) | 10 (3.6) |
Ischemic heart disease | 22 (7.9) | 36 (13.0) | 8 (2.9) |
Peripheral arterial occlusive disease | 18 (6.5) | 20 (7.2) | 0 |
Ischemic cerebrovascular disease | 13 (4.7) | 21 (7.6) | 1 (0.4) |
Other CVEs | 4 (1.4) | 4 (1.4) | 1 (0.4) |
CVEs by age at baseline | |||
Patients < 60 years, nb | 221 | 227 | 221 |
All CVEs | 26 (11.8) | 48 (21.1) | 5 (2.3) |
Ischemic heart disease | 12 (5.4) | 27 (11.9) | 5 (2.3) |
Peripheral arterial occlusive disease | 9 (4.1) | 15 (6.6) | 0 |
Ischemic cerebrovascular disease | 7 (3.2) | 16 (7.0) | 0 |
Other CVEs | 3 (1.4) | 3 (1.3) | 0 |
Patients ≥ 60 years, nb | 58 | 50 | 59 |
All CVEs | 20 (34.5) | 17 (34.0) | 5 (8.5) |
Ischemic heart disease | 10 (17.2) | 9 (18.0) | 3 (5.1) |
Peripheral arterial occlusive disease | 9 (15.5) | 5 (10.0) | 0 |
Ischemic cerebrovascular disease | 6 (10.3) | 5 (10.0) | 1 (1.7) |
Other CVEs | 1 (1.7) | 1 (2.0) | 1 (1.7) |
